<DOC>
	<DOC>NCT00057447</DOC>
	<brief_summary>Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland</brief_summary>
	<brief_title>Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Relapsed or progressive lowgrade/follicular NHL who are candidates for rituximab therapy Patients who were on other therapy including CHOP or radiation Previous therapy must have concluded 30 days prior to enrollment Demonstrable CD20positive tumor population in lymph nodes or bone marrow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>lymphoma</keyword>
</DOC>